Privosegtor Receives Breakthrough Drug Designation - Takeaways - MDSpire

Privosegtor Receives Breakthrough Drug Designation

In a phase 2 trial, the drug showed functional and structural signals in optic neuritis.

  • By

  • Conexiant News Staff

  • January 6, 2026

  • 2 min

Share

  • 1

    Oculis Holding AG's Privosegtor received FDA breakthrough therapy designation for treating optic neuritis.

  • 2

    Privosegtor is a peptoid small molecule aimed at neuroprotection for optic neuropathies.

  • 3

    The phase 2 ACUITY trial showed significant visual acuity improvement with Privosegtor compared to placebo.

  • 4

    The trial indicated preservation of retinal structure and reduced neurofilament release, a marker of injury.

  • 5

    Oculis initiated the PIONEER program for pivotal trials to support Privosegtor's registration in optic neuritis.

Original Source(s)

Privosegtor Receives Breakthrough Drug Designation

  • by Conexiant News Staff

  • January 6, 2026

Related Content

Retinal Changes Linked to PCOS

Meta-analysis of OCT and OCT angiography studies found thicker retinal nerve fiber layers and slightly thinner central macula in patients with polycystic ovary syndrome.

Single-cell transcriptomic profiling uncovers pathogenic cellular diversity and potential inflammatory markers in the retinas of STZ-induced diabetic mice

Impact of Anterior Retina Ablation on Anatomical Structures in Small Animal Models